Radiopharm Theranostics

RADX
SEC Registry CIK 0001949257
Development Stage Pre-commercial
Corporate Interface radiopharmtheranostics.com/

Clinical Pipeline

Program / Asset
Target Indications
Development Phase
RAD101
Brain Metastases
Preclinical
Phase 1
Phase 2
Phase 3
NDA
Approved
RAD202
HER2 Positive Solid Tumors
Preclinical
Phase 1
Phase 2
Phase 3
NDA
Approved
RAD204
PD-L1 Positive Solid Tumors
Preclinical
Phase 1
Phase 2
Phase 3
NDA
Approved
RAD301
Integrin αvβ6 Positive TumorsPancreatic cancer/ NSCLC
Preclinical
Phase 1
Phase 2
Phase 3
NDA
Approved
RAD402
KLK3 Positive Prostate Cancer
Preclinical
Phase 1
Phase 2
Phase 3
NDA
Approved
RV01
B7-H3 Positive Solid Tumors
Preclinical
Phase 1
Phase 2
Phase 3
NDA
Approved

Financial Statements & Analysis

[FINANCIAL_STATEMENT_INCOME]

Multi-Period Trend Analysis
REVENUE & GROSS PERFORMANCE
N/AN/AN/AN/A
Total Gross Revenue
— — — —
Cost of Revenue / Sales
— — — —
Gross Profit
— — — —
OPERATING EXPENSES
N/AN/AN/AN/A
Research & Development (R&D)
— — — —
Selling, General & Administrative (SG&A)
— — — —
Operating Income / (Loss)
— — — —
NON-OPERATING & FINANCING ITEMS
N/AN/AN/AN/A
Interest Income / Cash Yields
— — — —
Interest & Debt Servicing Expense
— — — —
Other Non-Operating Income / (Expense)
— — — —
Income Tax Provision / (Benefit)
— — — —
NET INCOME / (NET LOSS)
— — — —

[FINANCIAL_STATEMENT_BALANCE_SHEET_TRENDS]

Reporting Dynamic: Multi-Period Comparative
// PIPELINE_DISRUPTION: SNAPSHOT DISCLOSURES ABSENT

[FINANCIAL_STATEMENT_CASH_FLOWS]

Multi-Period Trend Analysis
OPERATING ACTIVITIES
N/AN/AN/AN/A
Net Income / (Loss)
— — — —
Depreciation & Amortization
— — — —
Stock-Based Compensation
— — — —
Change in Accounts Receivable
— — — —
Change in Prepaid Assets / Expenses
— — — —
Change in Payables & Clinical Accruals
— — — —
Net Cash from Operating Activities
— — — —
INVESTING ACTIVITIES
N/AN/AN/AN/A
Capital Expenditures (CapEx)
— — — —
Purchases of Marketable Securities
— — — —
Maturities & Sales of Investments
— — — —
Net Cash from Investing Activities
— — — —
FINANCING ACTIVITIES
N/AN/AN/AN/A
Proceeds from Issuing Debt Instruments
— — — —
Repayments of Debt / Leases
— — — —
Proceeds from Issuing Stock / ATM Options
— — — —
Net Cash from Financing Activities
— — — —
NET CONSOLIDATED CHANGE IN CASH
— — — —

Clinical Trials Registry

Registry ID
Phase / Asset
Status
NCT06777433
P-2 — RAD101
active not
NCT06824155
EARLY_P-1 — RAD202
recruiting
NCT06305962
EARLY_P-1 — RAD204
recruiting
NCT05799274
P-1 — RAD301
recruiting
NCT07259213
P-1 — RAD402
recruiting
NCT07189871
P-1 — RV01
recruiting

SEC EDGAR Disclosures

No SEC telemetry stream resolved for this entity.

Cross-Referenced Market Intelligence

Jun 5, 2026 Targeted Radiopharmaceuticals: Comparative Clinical Milestones of 177Lu-RAD202 and Iomab-B
RADX ATNM